Aquestive Therapeutics Statistics
Total Valuation
AQST has a market cap or net worth of $491.44 million. The enterprise value is $459.86 million.
| Market Cap | 491.44M |
| Enterprise Value | 459.86M |
Important Dates
The last earnings date was Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AQST has 125.69 million shares outstanding. The number of shares has increased by 24.83% in one year.
| Current Share Class | 125.69M |
| Shares Outstanding | 125.69M |
| Shares Change (YoY) | +24.83% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 4.04% |
| Owned by Institutions (%) | 53.02% |
| Float | 113.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.06 |
| Forward PS | 8.78 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.12
| Current Ratio | 6.12 |
| Quick Ratio | 5.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.73 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.63% |
| Return on Invested Capital (ROIC) | -276.30% |
| Return on Capital Employed (ROCE) | -54.63% |
| Weighted Average Cost of Capital (WACC) | 13.33% |
| Revenue Per Employee | $332,224 |
| Profits Per Employee | -$539,299 |
| Employee Count | 147 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 2.23 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.93% in the last 52 weeks. The beta is 1.50, so AQST's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -29.93% |
| 50-Day Moving Average | 4.37 |
| 200-Day Moving Average | 4.23 |
| Relative Strength Index (RSI) | 47.85 |
| Average Volume (20 Days) | 2,528,431 |
Short Selling Information
The latest short interest is 29.32 million, so 23.33% of the outstanding shares have been sold short.
| Short Interest | 29.32M |
| Short Previous Month | 27.60M |
| Short % of Shares Out | 23.33% |
| Short % of Float | 25.90% |
| Short Ratio (days to cover) | 13.74 |
Income Statement
In the last 12 months, AQST had revenue of $48.84 million and -$79.28 million in losses. Loss per share was -$0.64.
| Revenue | 48.84M |
| Gross Profit | 31.91M |
| Operating Income | -55.74M |
| Pretax Income | -79.28M |
| Net Income | -79.28M |
| EBITDA | -55.17M |
| EBIT | -55.74M |
| Loss Per Share | -$0.64 |
Balance Sheet
The company has $90.35 million in cash and $58.77 million in debt, with a net cash position of $31.58 million or $0.25 per share.
| Cash & Cash Equivalents | 90.35M |
| Total Debt | 58.77M |
| Net Cash | 31.58M |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | -70.82M |
| Book Value Per Share | -0.56 |
| Working Capital | 88.53M |
Cash Flow
In the last 12 months, operating cash flow was -$39.76 million and capital expenditures -$933,000, giving a free cash flow of -$40.70 million.
| Operating Cash Flow | -39.76M |
| Capital Expenditures | -933,000 |
| Depreciation & Amortization | 561,000 |
| Net Borrowing | 9.32M |
| Free Cash Flow | -40.70M |
| FCF Per Share | -$0.32 |
Margins
Gross margin is 65.34%, with operating and profit margins of -114.12% and -162.33%.
| Gross Margin | 65.34% |
| Operating Margin | -114.12% |
| Pretax Margin | -162.33% |
| Profit Margin | -162.33% |
| EBITDA Margin | -112.98% |
| EBIT Margin | -114.12% |
| FCF Margin | n/a |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -24.83% |
| Shareholder Yield | -24.83% |
| Earnings Yield | -16.37% |
| FCF Yield | -8.28% |
Analyst Forecast
The average price target for AQST is $9.33, which is 138.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.33 |
| Price Target Difference | 138.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 31.86% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AQST has an Altman Z-Score of -4.2 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.2 |
| Piotroski F-Score | 4 |